Long-term erythropoietin therapy does not affect metalloproteinases and their inhibitor levels, oxidative stress and inflammation in hemodialyzed patients

American Journal of Nephrology

Volumn 27, Issue 3, 2007, Pages 221-225

  Pawlak, Krystyna ^a   Pawlak, Dariusz ^a,b   Mysliwiec, Michal ^a  

^a Department of Nephrology and Clinical Transplantation ^*  (Poland)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Erythropoietin; Hemodialysis; Inflammation; MMPs TIMPs system; Oxidative stress

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; C REACTIVE PROTEIN; GELATINASE A; GELATINASE B; IRON; MERCURY; METALLOPROTEINASE; RECOMBINANT ERYTHROPOIETIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSCRIPTION FACTOR; ERYTHROPOIETIN; MALONALDEHYDE;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; INFLAMMATION; IRON THERAPY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK ASSESSMENT; BLOOD; CASE CONTROL STUDY; DRUG EFFECT; METABOLISM; MIDDLE AGED; RENAL REPLACEMENT THERAPY; UREMIA;

ADULT; AGED; ANEMIA; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; ERYTHROPOIETIN; FEMALE; HUMANS; MALE; MALONDIALDEHYDE; METALLOPROTEASES; MIDDLE AGED; OXIDATIVE STRESS; RENAL DIALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASES; UREMIA;

EID: 34250805332     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000101191     Document Type: Article

References (20)

1. Libby P: Changing concepts of atherogenesis. J Intern Med 2000;247:349-358.
2. Galis ZS, Sukhova GK, Lark MW, Libby P: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-2503.
3. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, Meyer J, Cambien F, Tiret L, Athero Gene Investigators: Plasma concentration and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003;107:1579-1585.
4. Pasterkamp G, Schoneveld AH, Hijnen DJ, de Kleijn DPV, Teepen H, van der Wal AC, Borst C: Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis 2000;150:245-253.
5. Zaltsman AB, George SJ, Newby AC: Increased secretion of tissue inhibitors of metalloproteinases 1 and 2 from the aortas of cholesterol fed rabbits partially counterbalances increased metalloproteinase activity. Arterioscler Thromb Vasc Biol 1997;19:1700-1707.
6. Canadian Erythropoietin Study Group: Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Br Med J 1990;300:573-578.
7. Sundal E, Businger J, Kappeler A: Treatment of transfusion-dependent anaemia of chronic renal failure with recombinant human erythropoietin. Nephrol Dial Transplant 1991;6:955-965.
8. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-590.
9. Nishiya D, Omura T, Shimada K, Matsumoto R, Kusuyama T, Enomoto S, Iwao H, Takeuchi K, Yoshikawa J, Yoshiyama M: Effects of erythropoietin on cardiac remodeling after myocardial infarction. J Pharmacol Sci 2006;101:31-39.
10. Stenvinkel P, Barany P: Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure: links to inflammation and oxidative stress. Nephrol Dial Transplant 2002;17(suppl 5):32-37.
11. Pawlak K, Pawlak D, My?liwiec M: Serum matrix metalloproteinase-2 and increased oxidative stress are associated with carotid atherosclerosis in hemodialysis patients. Atherosclerosis 2007;190:199-204.
12. Londero D, Lo Greco P: Automated high-performance liquid chromatographic separation with spectrofluorometric detection of a malondialdehyde-tiobarbituric acid adduct in plasma. J Chromatogr A 1996;729:207-210.
13. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995;47:186-192.
14. Pannen BH, Robotham JL: The acute phase response. New Horiz 1995;3:183-197.
15. Ludat K, Sommersburg O, Grune T, Siems WG, Riedel E, Hampl H: Oxidation parameters in complete correction of renal anemia. Clin Nephrol 2000;53:S30-S35.
16. Usberti M, Gerardi G, Bufano G, Tira P, Micheli A, Albertini A, Floridi A, Di Lorenzo D, Galli F: Effects of erythropoietin and vitamin E-modified membrane on plasma oxidative stress markers and anemia of hemodialyzed patients. Am J Kidney Dis 2002;40:590-599.
17. Cavdar C, Camsari T, Semin I, Gonenc S, Acikgoz O: Lipid peroxidation and antioxidant activity in chronic hemodialysis patients treated with recombinant human erythropoietin. Scand J Urol Nephrol 1997;31:371-375.
18. Siems W, Carluccio F, Radenkovic C, Grune T, Hampl H: Oxidative stress in renal anemia of hemodialysis patients is mitigated by epoetin treatment. Kidney Blood Press Res 2005;28:295-301.
19. Herrera J, Nava M, Romero F, Rodriguez-Iturbe B: Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am J Kidney Dis 2001;37:750-757.
20. Lim PS, Wei YH, Yu YL, Kho B: Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 1999;14:2680-2687.